FDA Approves Imjudo and Imfinzi in Combination with Chemotherapy for Patients with NSCLC

On November 10^th, 2022, the Food and Drug Administration (FDA) approved Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) and platinum-based chemotherapy for treatment of non-small cell lung cancer where there are no changes in ALK or EGFR. The FDA based their approval on the results of the clinical trial POSEIDON which showed that a high percentage of patients receiving the combination of Imjudo and Imfizni with chemotherapy experienced better outcomes as measured by higher overall survival and progression free survival when compared to those taking chemotherapy and a placebo. Additionally, patients receiving Imjudo, Imfizni and chemotherapy were more likely to respond to treatment.

The new approval gives patients new immunotherapy options. 

Learn more about this approval in the full FDA press release.

.fusion-body .fusion-builder-column-0{width:100% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-0 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1024px) {.fusion-body .fusion-builder-column-0{width:100% !important;order : 0;}.fusion-builder-column-0 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-0{width:100% !important;order : 0;}.fusion-builder-column-0 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}

.fusion-body .fusion-flex-container.fusion-builder-row-1{ padding-top : 0px;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}

The post FDA Approves Imjudo and Imfinzi in Combination with Chemotherapy for Patients with NSCLC appeared first on GO2 for Lung Cancer.

from GO2 for Lung Cancer https://ift.tt/mx7J2I1
via IFTTT